LIXT | Lixte Biotechnology Holdings, Inc.

Index- P/E- EPS (ttm)-0.36 Insider Own1.10% Shs Outstand16.65M Perf Week-1.47%
Market Cap11.00M Forward P/E- EPS next Y- Insider Trans24.98% Shs Float7.72M Perf Month21.60%
Income-6.00M PEG- EPS next Q- Inst Own3.90% Short Float / Ratio0.28% / 0.25 Perf Quarter-18.98%
Sales- P/S- EPS this Y20.10% Inst Trans-25.91% Short Interest0.02M Perf Half Y-12.42%
Book/sh0.03 P/B22.33 EPS next Y- ROA-97.40% Target Price- Perf Year-14.04%
Cash/sh0.25 P/C2.68 EPS next 5Y- ROE-263.30% 52W Range0.43 - 2.70 Perf YTD31.63%
Dividend- P/FCF- EPS past 5Y-15.50% ROI- 52W High-75.19% Beta-0.33
Dividend %- Quick Ratio17.30 Sales past 5Y- Gross Margin- 52W Low55.09% ATR0.09
Employees3 Current Ratio17.30 Sales Q/Q- Oper. Margin- RSI (14)51.67 Volatility17.37% 13.98%
OptionableNo Debt/Eq0.00 EPS Q/Q31.90% Profit Margin- Rel Volume5.32 Prev Close0.66
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume86.35K Price0.67
Recom- SMA205.04% SMA50-2.90% SMA200-1.72% Volume459,634 Change1.13%
Jun-02-23 12:30PM
May-30-23 08:30AM
Apr-24-23 08:30AM
Apr-04-23 08:30AM
Feb-14-23 01:50PM
05:26AM Loading…
Feb-08-23 05:26AM
Feb-07-23 12:58PM
Dec-05-22 08:30AM
Nov-30-22 08:05AM
Oct-13-22 08:30AM
Jun-21-22 08:30AM
Jun-15-22 08:30AM
Apr-14-22 06:45PM
10:54AM Loading…
Apr-13-22 10:54AM
Apr-12-22 03:20PM
Mar-22-22 08:30AM
Mar-16-22 08:30AM
Jan-12-22 08:30AM
Jan-05-22 09:18AM
Nov-22-21 09:25AM
Oct-20-21 09:25AM
09:25AM Loading…
Oct-13-21 09:25AM
Sep-24-21 09:31AM
Aug-17-21 11:02AM
Aug-03-21 09:25AM
Jul-22-21 09:25AM
Jul-13-21 09:25AM
Jul-07-21 09:35AM
Jun-26-21 05:45AM
Jun-03-21 08:22AM
Jun-02-21 09:35AM
May-18-21 05:30PM
May-12-21 09:35AM
May-04-21 04:30PM
Apr-28-21 09:35AM
Apr-13-21 09:35AM
Mar-17-21 09:35AM
Mar-03-21 09:35AM
Mar-02-21 06:38PM
Mar-01-21 08:45AM
Feb-26-21 11:58AM
Feb-25-21 02:37AM
Jan-19-21 09:35AM
Dec-01-20 03:28PM
Nov-30-20 03:52PM
Nov-25-20 08:30AM
Aug-18-20 09:35AM
Jul-21-20 09:35AM
Apr-30-20 10:30AM
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
van der Baan Bastiaan JeroenDirectorDec 30Buy4.9010,00049,00010,000Jan 04 11:09 AM
Bernards ReneDirectorDec 15Buy0.5115,0007,650150,000Dec 16 07:30 PM
Bernards ReneDirectorDec 12Buy0.6110,0006,100135,000Dec 13 11:44 AM
FORMAN ERICVice President and COONov 22Buy0.562,4841,391102,083Nov 23 04:29 PM
Brown ReginaDirectorNov 21Buy0.585,0002,8766,300Nov 22 10:18 AM
FORMAN ERICVice President and COONov 21Buy0.561,45781699,599Nov 23 04:29 PM
FORMAN ERICVice President and COONov 18Buy0.5616,2079,12598,142Nov 21 02:49 PM
FORMAN ERICVice President and COONov 17Buy0.544,8522,61981,935Nov 21 02:49 PM
Bernards ReneDirectorNov 14Buy0.5352,50027,825125,000Nov 15 07:44 PM